We expect to see such outcomes in rapid progressors of T1D, or high risk subjects that test positive to islet-specific (novel) autoantibodies such as those that are reactive to the extracellular domain of IA-2. The gene discussed is PTPRN; the disease is type 1 diabetes mellitus.